| abstract |
FIELD OF THE INVENTION The present invention relates to GLP (glucagon like peptide) and immunoglobulin hybrid Fc fusion polypeptides, and more particularly to a fusion polypeptide comprising GLP or an immunoglobulin hybrid Fc fusion polypeptide having increased half-life And a pharmaceutical composition for the treatment of diabetes mellitus, inflammatory bowel disease, enteric mucositis and diarrhea caused by chemotherapy or diarrhea comprising the fusion polypeptide. The fusion polypeptide of the present invention has an increased half-life as compared to the conventional GLP-1 or GLP-2, and has resistance to DPP-4, which is excellent for diabetes, inflammatory bowel disease, And diarrhea, or mononeurosis syndrome, and thus can be usefully applied to medicines. |